The twelve hallmarks of aging

Twelve biological processes, from DNA damage to worn-out stem cells, change with age and form the field's main map of why we age. The map is very good at telling you whether a product is aimed at real biology. It is much weaker on the question that matters to you: for most of the twelve, nobody has shown that fixing the process slows aging in people.

Use the list as a filter, not a shopping list. The levers that touch many hallmarks at once (regular exercise, a Mediterranean-style diet, enough sleep and less visceral fat) are the best supported: human studies show them improving markers of several hallmarks, though none has been shown to slow aging itself. No drug or supplement aimed at a single hallmark has yet been shown to slow aging in healthy adults. Treat anything sold as "targets the hallmarks of aging" as a claim about mechanism, not about results.

What the hallmarks are, and what they aren't

The framework was introduced by López-Otín and colleagues in 2013 and expanded to twelve hallmarks in 2023.[1] It sorts them into three groups: five primary hallmarks (the damage itself), three antagonistic ones (responses to damage that help at first and harm when they persist), and four integrative ones (system-wide consequences once the damage can no longer be compensated).[2]

To count as a hallmark, a process must:

  1. Appear naturally during aging
  2. Speed up aging when experimentally made worse
  3. Slow aging and extend healthspan when targeted

It is a descriptive map, not a proven theory of what causes aging, and which hallmarks drive aging rather than accompany it is disputed (see the last section).

Every hallmark below carries two ratings: Descriptive (how sure we are the process happens and tracks with aging) and Intervention (how sure we are that doing something about it slows aging). The descriptive side is solid: most of the twelve really do change with age and track with age-related disease. For several hallmarks, though, the first rating is Strong and the second Weak or absent, and that gap is the most important thing on this page.

The damage: five primary hallmarks

1. Genomic instability. Descriptive Strong; Intervention Weak. DNA damage from toxins, ultraviolet light and the body's own oxidative stress builds up as repair systems become error-prone. The damage doesn't stay local: DNA fragments that leak out of the nucleus or mitochondria are mistaken for a virus by the immune system, feeding body-wide inflammation. A Mediterranean-style diet, fewer environmental toxins, enough sleep (DNA repair is thought to run hardest during sleep) and exercise are the usual levers, but no human trial shows that reducing DNA damage slows aging. See Genomic instability.

2. Telomere attrition. Descriptive Strong; Intervention Caution, and the safe route is indirect. Telomeres are protective caps on chromosome ends that shorten with each cell division, and short telomeres go with heart disease, dementia and earlier death. But the genetics cut both ways: people who inherit longer telomeres get fewer degenerative diseases but more cancers,[3] with no clear net effect on lifespan.[4] So "longer is better" is false, consumer telomere tests are too noisy to act on, and drugs that switch telomerase back on carry real cancer concerns. Chronic inflammation is the leading suspect for how lifestyle affects telomeres, though that rests on one snapshot analysis, and pooled exercise trials point to only a small benefit held with low confidence. See Telomere attrition.

3. Epigenetic alterations. Descriptive Strong; Intervention Moderate. The chemical tags that tell each cell which genes to use drift with age, silencing some protective genes while losing control of others. Because these marks are reversible, this is the most treatable primary hallmark, and it is the one epigenetic clocks read (covered below). See Epigenetic alterations.

4. Loss of proteostasis. Descriptive Moderate; Intervention none proven in mammals. Protein quality control fails and misfolded protein clumps build up, the defining lesion of Alzheimer's and Parkinson's. The evidence is thinner than the story: one mouse study found no universal decline, and by age 90 a large minority of people with normal thinking carry amyloid. Boosting protein quality control extends life in worms and flies but not convincingly in mammals, where a single small, unrepeated mouse study claims longer life, and the supplement trials aimed here have missed. Sauna, spermidine and deep sleep rest on mechanism, not outcomes. The one real success is in transthyretin amyloidosis, where drugs that hold a single misfolding protein in shape (tafamidis, acoramidis) or stop the body making it (vutrisiran) beat placebo in company-funded trials, and two of them cut deaths; a second silencer, eplontersen, missed its main goal.[5][6] That works because there is one culprit protein, the opposite of a general fix for aging. See Loss of proteostasis.

5. Disabled macroautophagy. Descriptive Strong; Intervention Moderate for exercise, Weak for fasting and every drug and supplement, Caution on chronic rapamycin. Autophagy is the cell's recycling program for worn-out proteins and mitochondria. It is thought to slow with age, and the 2023 update made it a hallmark in its own right. Exercise is the one lever with human muscle-biopsy data. Calorie restriction and time-restricted eating switch it on in animals. Spermidine extends lifespan in animals, but the trial the field wanted, in 100 older adults over 12 months, improved neither memory nor the biomarkers. Autophagy can so far be measured only in cells taken out of the body, mostly blood cells, so no test can show whether it is working better in a person's tissues. See Disabled macroautophagy.

The responses: three antagonistic hallmarks

6. Deregulated nutrient sensing. Descriptive Strong; Intervention Strong in mice, Weak in humans. The cell's growth signals (built around mTOR) and its repair signals (built around AMPK and the sirtuins) fall out of balance; constant food surplus keeps growth on and repair suppressed. The goal is to swing between the two, not to suppress growth for good. Too little growth signalling brings frailty, muscle loss and weaker immunity, and in 960 genetically diverse female mice the deepest restriction extended life most but cost lean mass and shifted the immune system, with genetics mattering more than diet. See Deregulated nutrient sensing.

The levers are calorie restriction, fasting and time-restricted eating; exercise, the most reliable way to switch on AMPK; and drugs. Rapamycin, which blocks mTOR directly, extends mouse lifespan reproducibly but has not delivered in people.[7] Both placebo-controlled trials of weekly rapamycin missed their main goal. A weaker, low-dose compounded version did not change visceral fat,[8] and in a small 13-week trial in adults aged 65–85, standard rapamycin added nothing to home exercise, may have slightly reduced its benefit, and caused more side-effect events than placebo.[9] A 1,000-person trial of another drug on the same pathway did not reduce respiratory illness.[10] Metformin acts on AMPK, but the early hint that people with diabetes taking it outlived people without diabetes did not hold up when re-tested in Danish national registers.[11] GLP-1 drugs slowed several clocks only in an after-the-fact analysis of a small trial in adults with HIV-related fat redistribution, with the clocks run by a commercial vendor.[12]

7. Mitochondrial dysfunction. Descriptive Strong; Intervention Moderate. Damaged mitochondria make less energy and leak fragments the immune system treats as danger signals. The key idea is mitohormesis: brief, controlled stress triggers renewal — exercise has the human evidence, and fasting, heat and cold are thought to act the same way — which is also why high-dose antioxidants don't help. Aerobic exercise — zone 2 training and intervals alike — builds new mitochondria by about the same amount, with total training load the best predictor;[13] there is no human lifespan data. The pills disappoint. Urolithin A missed both primary endpoints in 66 older adults. When trials of the NAD⁺ precursors NMN and NR in older adults were pooled, they did not improve muscle mass, grip strength or physical function; in people with mild cognitive impairment, NR was linked to slightly worse physical performance.[14] See Mitochondrial dysfunction.

8. Cellular senescence. Descriptive Strong; Intervention Strong in mice, Weak in humans, with a reason for Caution. Senescent "zombie" cells stop dividing but keep pumping out inflammatory signals. Useful in youth for wound healing and blocking tumours, they do harm as they pile up. Senolytic drugs that kill them, such as dasatinib plus quercetin, work strikingly well in mice. In people, the flagship knee-osteoarthritis trial missed, and a 20-week randomised trial in 60 postmenopausal women did not slow bone breakdown.[15] And in 19 healthy adults with no comparison group, six months of dasatinib plus quercetin sped up several epigenetic clocks and lowered a methylation estimate of telomere length, though the clocks best linked to health outcomes did not move.[16] Healthy adults should not self-dose these; see Cellular senescence.

The consequences: four integrative hallmarks

9. Stem-cell exhaustion. Descriptive Strong; Intervention Weak. The stem cells that repair muscle, gut and blood run down. Resistance training keeps muscle stem cells working; regular, unbroken sleep protects blood-forming stem cells in mice;[17] moderate calorie restriction helps in animals. Stem-cell therapy is still experimental: in the best trial, one infusion of donor stem cells in 148 frail older adults missed its main six-month comparison, and the walking gain seen at nine months in the highest-dose group, only 16 people, is a single company-funded result, not proof that the therapy slows aging.[18] Unapproved stem-cell injections are sold by thousands of clinics and have a documented harm record, including deaths and several cases of blindness from injections into the eye. See Stem-cell exhaustion.

10. Altered intercellular communication. Descriptive Moderate; Intervention Weak. Signalling between tissues degrades, and in experiments joining old and young animals, old blood carries factors that drive decline. The closest human test was a small, not truly randomised trial of plasma exchange, which dilutes old-blood factors, run by authors linked to a plasma-exchange company. Clock readings improved against a sham at the midpoint but not by the end, and no health outcomes were measured.[19] "Rejuvenation" plasma exchange is running ahead of this evidence. The practical levers are hormone treatment where medically indicated (menopausal hormone therapy in the right window, testosterone for symptomatic deficiency, thyroid), lower inflammation and social engagement (Purpose). See Altered intercellular communication.

11. Chronic inflammation ("inflammaging"). Descriptive Strong; Intervention Moderate. A low-grade, persistent inflammation, fed by senescent cells, leaked mitochondrial DNA and a leaky gut, pervades aging tissue. It is closely linked to clogged arteries, osteoarthritis, insulin resistance and neurodegeneration, and the biology of how it could drive them is well worked out.[20] It is still a model, though: lifestyle lowers inflammation markers, but nobody has shown that lower markers prevent these diseases. A Mediterranean diet, exercise, consistent sleep, less visceral fat and omega-3 fats are the levers. Fasting seems to help only through the fat loss: a 12-month trial found neither time-restricted eating nor ordinary calorie restriction changed inflammatory signals. See Chronic inflammation.

12. Dysbiosis. Descriptive Moderate; Intervention Weak, among the least causally established. With age the gut microbiome tends to lose bacteria that make short-chain fatty acids and gain potentially harmful species, though the changes vary from study to study.[21] Not every helpful species declines: in one Italian study, the barrier-supporting Akkermansia was more common in people aged 105 to 109.[22] In old mice a leakier gut lets bacterial products into the blood and feeds inflammaging;[23] in people that link shows up mainly in the frail or ill. High-fibre food, fermented foods, avoiding needless antibiotics and possibly specific probiotic strains are the levers. See Dysbiosis.

Epigenetic clocks: the best biomarkers, with real limits

Clocks such as Horvath, GrimAge and DunedinPACE read DNA methylation patterns to estimate biological age, and they are the most developed human biomarkers of aging.[24][25][26] The newer clocks trained on health outcomes predict disease and death better than the originals trained on calendar age.[27]

Three limits matter for anyone buying a test. Measuring the same blood sample twice can give ages several years apart on the older clocks, while GrimAge and DunedinPACE are much more consistent.[28] In one US cohort of adults over 50, a score built from seven inflammation blood measures predicted four-year mortality slightly better than the six clocks it was compared with,[29] while in about 1,100 Berliners aged 60 to 80 followed for about seven years, the pace-of-aging clock DunedinPACE was the strongest predictor of death among 14 proposed aging markers, so no single marker reliably wins and the result may depend on the group and the clock.[30] And no clock has been shown to work as a stand-in for real outcomes: nobody has shown that lowering your score lowers your risk, so a "younger" result after a supplement is not evidence that it helps.[31][32]

What has moved a clock. Sustained calorie restriction in healthy, non-obese adults aged 21–50 slowed the DunedinPACE clock by a few percent over two years, though people managed only about 12% restriction against a 25% target, the analysis was done after the fact, and two other clocks did not change.[33] In Swiss adults over 70, 1 g of omega-3 a day over three years slowed clocks slightly, while vitamin D and a home exercise programme moved none on their own.[34] A daily multivitamin slowed two of five clocks over two years.[35] Everything else has only weak direct evidence: fasting, exercise (linked to younger readings in observational studies, but not shown to slow clocks on its own in a trial), methyl-donor nutrients such as folate, B12 and choline, and cutting added sugar, where one cross-sectional study of 342 midlife women tied more sugar to a slightly older GrimAge reading.[36] Partial reprogramming, briefly switching on genes that can reset a cell to an embryo-like state, is experimental, with major safety concerns.

DamAge and AdaptAge are newer clocks built from methylation sites that genetic methods suggest drive aging, split into damaging changes and protective adaptations.[37] They suggest interventions might work by boosting adaptation, but that is a hypothesis: nobody has shown that raising AdaptAge-type marks extends healthspan. A sister clock from the same paper was among the less reliable of 18 clocks in a 2026 test, run by authors who develop a competing clock.[38] For now these are research tools, not personal tests.

Heart rate variability is a cheaper, trackable proxy, linked to aging through the nervous system and inflammation. One study of about 1,060 healthy adults built an "autonomic age" from 29 heart and blood-pressure measures, and people with a high-risk cardiovascular profile scored about 11 years older than their calendar age, low-risk people about a year younger.[39] It is a single cross-sectional study using lab measurements, not a wearable. See Heart rate variability.

Which interventions hit which hallmarks

InterventionHallmarks targeted
Mediterranean / MIND dietInflammation, dysbiosis, epigenetic alterations, genomic instability
Aerobic exerciseMitochondria, telomeres, inflammation, autophagy
Resistance trainingStem cells (muscle), intercellular communication
Fasting / time-restricted eatingNutrient sensing, autophagy, epigenetic, mitochondria. Mechanism robust, no human lifespan trial; the CALERIE clock result belongs to sustained calorie restriction, not fasting
SleepGenomic instability (DNA repair), proteostasis (overnight brain clearance), inflammation
SaunaProteostasis, inflammation — mechanistic
Cold exposureMitochondria (modest) — mechanistic; no human longevity data
RapamycinNutrient sensing, autophagy — extends lifespan in mice; both placebo-controlled trials of weekly rapamycin so far missed their main goal
MetforminNutrient sensing, inflammation
GLP-1 drugsNutrient sensing, inflammaging — slowed clocks in one after-the-fact analysis in a special population; wider hallmark claims are not supported
SenolyticsCellular senescence
NAD⁺ precursorsMitochondria — mechanistic; pooled trials in older adults show no gain in muscle or function

There is no single master switch for aging. Lifestyle levers each touch several hallmarks, one reason they outperform single-molecule products. Fasting and cold have real mechanisms but no human longevity-outcome trial; fasting carries safety caveats (an observational signal of higher cardiovascular death with very short eating windows, and a refeeding cell-growth concern), and cold's metabolic and anti-inflammatory claims largely don't survive scrutiny. Drugs are not ready for healthy adults without a specific medical reason.

Where the framework is contested

The evidence is not evenly strong across the twelve. The third test, that treating a hallmark slows aging, comes closest to being met in mice, for rapamycin and senolytics. Even there, most studies use lifespan as a stand-in for aging and rarely treat young animals too, so they can't tell "slowed aging" from "fixed a problem that would improve at any age"; in one large mouse study, only some of rapamycin's benefits looked like slowed aging.[40] For dysbiosis and intercellular communication the evidence is still largely correlative.

The hallmarks describe; they don't explain. Critics argue the scheme borrows its authority from the hallmarks of cancer, call it somewhat arbitrary and incomplete, and say it quietly assumes the contested damage theory of aging.[41] A minority holds that aging is the harmful continuation of growth programs rather than damage, in which case some hallmarks are consequences, not causes.[42] Telling drivers of aging from passengers is unresolved.[43] A survey of aging biologists found no majority view on what aging is, what causes it or what counts as rejuvenation.[44]

There are other maps, and organs age at different speeds. The seven pillars of geroscience stress how the processes connect,[45] the Hallmarks of Health describe what keeps the body working,[46] and heart and brain have their own hallmark sets.[47][48] In mice, age-related changes in gene activity do not run in step across organs.[49] In people, models that estimate each organ's age from blood proteins found nearly one adult in five had a single organ aging much faster than the rest, and people with more "old" organs were more likely to die during follow-up.[50][51] These are observational findings, and several of the researchers hold equity in a company developing the method, but they are a good reason to distrust any test that sums you up as one "biological age".

The authors have interests too. Per the 2023 paper's declarations, several authors hold equity in companies built around specific hallmarks: Maria Blasco founded a telomere-measurement company, Manuel Serrano advises and holds shares in senescence- and reprogramming-focused firms, and Guido Kroemer co-founded several biotech companies and holds patents on targeting aging. Carlos López-Otín and Linda Partridge declared none. This is context, not grounds to discount the framework.

Further reading

  • López-Otín C et al. The Hallmarks of Aging. Cell 2013.[52]
  • López-Otín C et al. Hallmarks of aging: An expanding universe. Cell 2023.[53]
  • Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 2013.[54]
  • Belsky DW et al. DunedinPACE — a DNA methylation biomarker of the pace of aging. eLife 2022.[55]
  • Ying K et al. Causality-enriched epigenetic age uncouples damage and adaptation (DamAge / AdaptAge). Nature Aging 2024.[56]
  • Waziry R, Belsky DW et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging (CALERIE trial). Nature Aging 2023.[57]
  • Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nature Aging 2023.[58]
  • Gems D, de Magalhães JP. The hoverfly and the wasp: a critique of the hallmarks of aging as a paradigm. Ageing Research Reviews 2021.[59]
  • de Magalhães JP. Distinguishing between driver and passenger mechanisms of aging. Nature Genetics 2024.[60]
  • Gladyshev VN et al. Disagreement on foundational principles of biological aging. PNAS Nexus 2024.[61]
  • Kennedy BK, Berger SL, Brunet A et al. Geroscience: linking aging to chronic disease (the seven pillars). Cell 2014.[62]
  • López-Otín C, Kroemer G. Hallmarks of Health. Cell 2021.[63]

— § —